KYBORA is pleased to announce the licensing of Daewoong’s development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China region.
KYBORA and its Chinese translation (pronounced KAI-BO-RUI) have both been granted official trademark status by the People’s Republic of China.
KYBORA is please to announce that its client Pint Pharma has completed an agreement to commercialize Orladeyo in Latin America
KYBORA is pleased to announce the global licensing of ACT-01 from Accure Therapeutics to Oculis. This transaction further demonstrates KYBORA’s expertise in delivering global biopharma licensing deals and in the ophtalmology space
Princeton, NJ – October 12th, 2021 KYBORA is pleased to […]
KYBORA is pleased to announce that Dr. Leonid Parshenko […]
Download full presentation here
Recently, KYBORA Managing Director Jean Chatellier had […]
KYBORA is pleased to announce that Damien Villeneuve ha […]
KYBORA GmbH is pleased to announce that Jean-Baptiste D […]
